Trade and economic implications of low level presence and asynchronous authorizations of agricultural biotech crops in China

J Huang,J Yang
DOI: https://doi.org/10.18278/wfp.1.2.2
2014-01-01
World Food Policy
Abstract:China has developed its own strong biotech program as well as a biosafety regulation system for genetically modified (GM) commercial production and import, but has yet started to seek approval for its GM events in any foreign country. China's biosafety regulations on biotech crop import, which requires that import applications start after approval from the country of origin and the zero tolerance rule, will have important implications for major GM producing countries that export GM products to China in terms of trade, price, and production and also to China itself in terms of food price and economic welfare. As China continues to expand its biotech crop commercialization, to minimize its trade conflicts with its exporting destination countries, China may also need to revisit its current policy of not seeking approval for its GM events in its major export destination countries in the future. A less trade‐distorted regulation on low level presence (LLP) can benefit from the comparative advantage of agricultural production, stabilized domestic food price, and increased total social welfare. Global cooperation should be set up to enhance the safety management and also lower the multifarious and unnecessary costs of LLP.
What problem does this paper attempt to address?